Aurora kinase A is a synthetic lethal target in FANCA-deficient cancers.
Cancers lacking the FANCA gene show vulnerability to a specific kinase inhibitor, suggesting a new precision strategy for multiple tumor types.
Using complementary CRISPR and drug screen platforms in isogenic cancer models, this study identifies Aurora kinase A as a new synthetic lethal vulnerability in FANCA-deficient cancers—a genotype present across multiple tumor types in large-scale clinical sequencing databases. The mechanistic link between FANCA deficiency, elevated AURKA expression, and mitotic instability provides a clear molecular rationale for clinical trials combining AURKA inhibitors with patient stratification by FANCA status.
What the study was
- Study design
- preclinical_with_genomic_validation
- Population
- FANCA-deficient cancer cell lines; clinical genomic databases
- Sample size
- >650,000 sequenced tumors (genomic analysis component)
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- NPJ Precision Oncology
Why it surfaced
FANCA loss-of-function is prevalent across many cancer types per large-scale clinical genomics; AURKA inhibitors exist (alisertib); this identifies a new patient selection biomarker for repurposing; preclinical rigor (CRISPR screen + drug screen + 650K sequenced tumors) is high; Rubin/Rottenberg labs at Bern are leading precision oncology groups.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.